DE602005020112D1 - Derivate von pyridin und chinolin - Google Patents

Derivate von pyridin und chinolin

Info

Publication number
DE602005020112D1
DE602005020112D1 DE602005020112T DE602005020112T DE602005020112D1 DE 602005020112 D1 DE602005020112 D1 DE 602005020112D1 DE 602005020112 T DE602005020112 T DE 602005020112T DE 602005020112 T DE602005020112 T DE 602005020112T DE 602005020112 D1 DE602005020112 D1 DE 602005020112D1
Authority
DE
Germany
Prior art keywords
chinoline
pyridine
derivatives
blocking
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005020112T
Other languages
German (de)
English (en)
Inventor
Sanjuan Juan Carlos Lacal
Rosa Joaquin Campos
Meza Miguel Angel Gallo
Ubeda Antonio Espinosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Granada
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Granada filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of DE602005020112D1 publication Critical patent/DE602005020112D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/44Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE602005020112T 2004-01-14 2005-01-11 Derivate von pyridin und chinolin Expired - Lifetime DE602005020112D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400072A ES2237332B1 (es) 2004-01-14 2004-01-14 Derivados de piridinio y quinolinio.
PCT/ES2005/070002 WO2005068429A1 (es) 2004-01-14 2005-01-11 Derivados de piridinio y quinolinio

Publications (1)

Publication Number Publication Date
DE602005020112D1 true DE602005020112D1 (de) 2010-05-06

Family

ID=34778265

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005020112T Expired - Lifetime DE602005020112D1 (de) 2004-01-14 2005-01-11 Derivate von pyridin und chinolin

Country Status (15)

Country Link
US (1) US7781458B2 (https=)
EP (2) EP2085386A3 (https=)
JP (2) JP5047627B2 (https=)
KR (1) KR101157206B1 (https=)
CN (1) CN1910153B (https=)
AT (1) ATE461918T1 (https=)
BR (1) BRPI0506486A (https=)
CA (1) CA2553328C (https=)
DE (1) DE602005020112D1 (https=)
DK (1) DK1710236T3 (https=)
ES (2) ES2237332B1 (https=)
MX (1) MXPA06007940A (https=)
PL (1) PL1710236T3 (https=)
PT (1) PT1710236E (https=)
WO (1) WO2005068429A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586613B2 (en) * 2004-01-14 2013-11-19 Universidad De Granada Pyridinium and quinolinium derivatives
AU2009265121A1 (en) 2008-07-04 2010-01-07 Traslational Cancer Drugs Pharma, S.L. Methods for the treatment and diagnosis of cancer
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
US20110212994A1 (en) * 2009-06-26 2011-09-01 Brian Clem Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders
WO2012041493A1 (en) * 2010-09-28 2012-04-05 Julius-Maximilians-Universität Würzburg Aminoquinolinium salts, methods of their production and their use as active agents for biotechnological and medical applications against binary toxins
EP2468259A1 (en) 2010-12-23 2012-06-27 Traslational Cancer Drugs Pharma, S.L. Pharmaceutical compositions of pyridinium and quinolinium derivatives
JP2014527397A (ja) 2011-06-20 2014-10-16 トラスラショナル、キャンサー、ドラッグス、ファーマ、ソシエダッド、リミターダTraslational Cancer Drugs Pharma, S.L. 癌患者の化学療法に対する臨床応答を予測する方法
US20130281445A1 (en) * 2011-09-22 2013-10-24 Simon Everitt Compounds useful as inhibitors of choline kinase
ES2472367B1 (es) * 2012-12-28 2015-06-02 Universidad De Granada Inhibidores no simétricos de colina quinasa con actividad antitumoral y antimalárica
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
ES2482290B1 (es) * 2014-06-05 2015-05-19 Universidad De Granada Inhibidores polares simétricos de colina cinasa con actividad antitumoral
US10683292B2 (en) 2016-07-25 2020-06-16 Nerviano Medical Sciences S.R.L. Purine and 3-deazapurine analogues as choline kinase inhibitors
CN110997678B (zh) 2017-07-11 2023-02-21 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的吡唑并喹唑啉衍生物
WO2025196502A1 (en) * 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206215A (en) * 1976-02-25 1980-06-03 Sterling Drug Inc. Antimicrobial bis-[4-(substituted-amino)-1-pyridinium]alkanes
GB1533952A (en) * 1976-02-25 1978-11-29 Sterling Drug Inc Anti-microbial bis-pyridinium compounds
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
GT198900005A (es) * 1988-01-29 1990-07-17 Quinolinas y cinolinas substituidas.
ES2117950B1 (es) * 1996-08-02 1999-09-16 Univ Granada Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular.

Also Published As

Publication number Publication date
CA2553328C (en) 2012-05-15
ES2237332B1 (es) 2006-11-01
CN1910153A (zh) 2007-02-07
DK1710236T3 (da) 2010-07-12
EP1710236B1 (en) 2010-03-24
CA2553328A1 (en) 2005-07-28
EP1710236A1 (en) 2006-10-11
KR101157206B1 (ko) 2012-07-06
PT1710236E (pt) 2010-06-18
JP2007517837A (ja) 2007-07-05
JP5047627B2 (ja) 2012-10-10
ES2343418T3 (es) 2010-07-30
EP2085386A2 (en) 2009-08-05
CN1910153B (zh) 2010-05-26
JP2012149077A (ja) 2012-08-09
US20070185170A1 (en) 2007-08-09
KR20060110364A (ko) 2006-10-24
EP2085386A3 (en) 2009-10-28
ES2237332A1 (es) 2005-07-16
ATE461918T1 (de) 2010-04-15
US7781458B2 (en) 2010-08-24
BRPI0506486A (pt) 2007-02-13
MXPA06007940A (es) 2007-01-23
WO2005068429A1 (es) 2005-07-28
HK1100441A1 (en) 2007-09-21
JP5619805B2 (ja) 2014-11-05
PL1710236T3 (pl) 2010-08-31

Similar Documents

Publication Publication Date Title
DE602005020112D1 (de) Derivate von pyridin und chinolin
CY1121202T1 (el) ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b)]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΗΣ JANUS
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
CY1112402T1 (el) Ενισχυτες υποδοχεων γλουταμικου
SE0301373D0 (sv) Novel compounds
CY1111083T1 (el) Παραγωγα νικοτιναμιδιου χρησιμα ως αναστολεις της p38
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
BR0318383A (pt) derivados de pirazoloisoquinolina como inibidores de cinase
BRPI0506736A (pt) composto estereoisoméricos e métodos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
NO20070726L (no) Koblede pyrimidoner anvendbare i behandling eller forebygging av kreft
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
EA201170344A1 (ru) Азаиндольные ингибиторы iap
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
EA201300740A1 (ru) Замещенные пиридины, обладающие гербицидной активностью
EA201590074A1 (ru) Производное бензодиоксола, способ его получения и его применение
BRPI0608216A2 (pt) agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
EP1602669A4 (en) ANTIBODIES TO TUMOR-SPECIFIC ANTIGEN AS TARGET
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
DE602005005967D1 (de) Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition